glycerol phenylbutyrate

glycerol phenylbutyrate

(gli-ser-ol fen-il-bue-ti-rate) ,


(trade name)


Therapeutic: orphan drugs
Pharmacologic: temporary class
Pregnancy Category: C


Chronic treatment of hyperammonemia associated with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation, which must be continued.Not to be use for acute treatment of hyperammonemia.


Binds nitrogen

Therapeutic effects

Decreased ammonia levels with decreased sequelae of hyperammonemia.


Absorption: Well absorbed following oral administration
Distribution: Unknown.
Protein Binding: PBA—80.6–98%
Metabolism and Excretion: Glycerol phenylbutyrate is a triglyceride prodrug that releases phenylbutyrate (PBA) following the action of lipases in the GI tract. Further metabolism results in conversion to phenylacetate (PAA), the active moiety. PAA binds glutamine in the liver and kidneys forming phenylacetylglutamine (PAGN), which is then renally eliminated (68.9%). Women form a higher percentage of metabolites.
Half-life: Unknown.

Time/action profile (PAA levels)

POunknown4 hr8 hr


Contraindicated in: Known hypersensitivity to phenylbutyrate (wheezing, dyspnea, coughing, hypotension, flushing, nausea, rash) Lactation: Avoid breastfeeding Pediatric: Age <2 mos
Use Cautiously in: Moderate to severe hepatic impairment (initiate treatment at low end of dose range)Pancreatic insufficiency/ intestinal malabsorption (may ↓ absorption of phenylbutyrate).Renal impairment (monitor ammonia levels carefully) Geriatric: Consider age-related decrease in renal/hepatic/cardiac function, concurrent disease states and medications. Obstetric: Use only if maternal benefit justifies potential fetal risk.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • fatigue (↑ in adults) (most frequent)


  • abdominal pain (↑ in children) (most frequent)
  • ↓ appetite (most frequent)
  • diarrhea (most frequent)
  • flatulence (most frequent)
  • nausea (most frequent)
  • dyspepsia
  • vomiting


  • rash (↑ in children) (most frequent)


  • hyerammonemia (most frequent)


  • neurotoxicity


Drug-Drug interaction

Ammonia levels may be↑ by corticosteroids,.haloperidol or valproic acid, monitor carefully.Probenecid ↓ renal excretion of metabolites PAGN and PAA.


Total daily dose is given in three equally divided doses, adjustments based on plasma ammonia, urinary phenylacetylglutamine or plasma phenylacetate. Consider estimated ability to synthesize urea, dietary protein intake and adherence to dietary recommendations.
Oral (Adults and Children ≥2 yr) Swtiching from sodium phenylbutyrate—total daily dose of glycerol phenylbutyrate = daily dose of sodium phenylbutyrate (g) x 0.86; initial dose in phenylbutyrate naïve patients—4.5–11.2 mL/m2/day (5–12.4 g/m2/day). Total daily dose is divided into three equal doses, rounded up to the nearest 0.5 mL.

Hepatic Impairment

Oral (Adults and Children ≥2 yr) Initiate therapy at lower end of dose range.


Oral liquid: 1.1 g/mL

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of high blood ammonia (headache, feeling tired, lightheadedness, confusion) periodically during therapy.
  • Monitor for signs and symptoms of neurotoxicity (somnolence, fatigue, lightheadedness, headache, dysgeusia, partial hearing loss, disorientation, impaired memory, exacerbation of preexisting neuropathy). May be seen with plasma PAA concentrations ≥500 mcg/mL.
  • Lab Test Considerations: Monitor fasting plasma ammonia levels frequently during dose changes. less than half the upper limit of normal according to age.
    • Urinary phenylacetylglutamine (U-PAGN) may be used to help guide dosing. Each gram of U-PAGN excreted over 24 hr covers waste nitrogen generated from 1.4 grams of dietary protein. If U-PAGN excretion is insufficient to cover daily dietary protein intake and fasting ammonia is > half upper limit of normal, adjust dose of glycerol phenylbutyrate upward. Factor in amount of dietary protein not covered in dose adjustment indicated by 24-h U-PAGN level.
    • Monitoring plasma PAA levels can assist with dosing if side effect occur. Ratio of PAA to PAGN in plasma may also assist in dose adjustment.

Potential Nursing Diagnoses

Deficient knowledge, related to diet and medication regimen (Patient/Family Teaching)


  • Glycerol phenylbutyrate should only be prescribed by clinicians with experience treating patients with urea cycle disorders.
  • Oral: Administer with food and directly into mouth via oral syringe or dosing cup. Store at room temperature.
    • For administration via nasogastric or gastrostomy tube, use oral syringe to withdraw dose, place tip of syringe into tip of gastrostomy/nasogastric tube. Use plunger of syringe to administer medication into tube. Flush once with 30 mL of water and allow flush to drain. Flush a second time with an additional 30 mL of water to clear tube.

Patient/Family Teaching

  • Instruct patient to take glycerol phenylbutyrate as directed along with dietary protein restriction and, if prescribed, dietary supplements (essential amino acids, arginine, citrulline, protein-free calorie supplements). Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
  • Advise patient to notify health care professional promptly if signs and symptoms of neurotoxicity (sleepiness, worsening neuropathy, weakness, numbness, tingling, lightheadedness, burning in hands or feet, change in taste, problems with hearing, headache, confusion, problems with memory) occur.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
  • Encourage patients to enroll in a UCD registry to collect information about people with UCD to improve care. Contact registry by calling 1-855-823-2595 or visit

Evaluation/Desired Outcomes

  • Decreased ammonia levels for a fasting plasma ammonia level less than half the upper limit of normal according to age with decreased sequelae of hyperammonemia. If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other illnesses, reduce dose of glycerol phenylbutyrate.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
M2 PHARMA-December 28, 2018-Horizon Pharma Receives FDA Nod to Expand the Age Range for Raviciti (glycerol phenylbutyrate) Oral Liquid to Include Newborns
Ravicti (glycerol phenylbutyrate) and Ammonaps (sodium phenylbutryate) are indicated for the treatment of Urea Cycle Disorders (UCD), a group of serious conditions in which patients suffer from deficiencies in the enzymes required to remove ammonia from the blood stream.
Glycerol phenylbutyrate, a nitrogen-binding agent, has been approved for the chronic treatment of adults and children aged 2 years and older with urea cycle disorders, who cannot be managed with a protein-restricted diet or amino acid supplements alone, according to the Food and Drug Administration.
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) reported on Thursday the launch of RAVICTI (glycerol phenylbutyrate) Oral Liquid in Canada in partnership with its Horizon Therapeutics Canada Limited affiliate for the treatment of Urea Cycle Disorders (UCDs).
Based on the Canadian approval, RAVICTI (glycerol phenylbutyrate) will be added to the Register of Innovative Drugs and receive data protection for a term of up to eight years from the date of the issuance of the NOC, added the company.
M2 EQUITYBITES-March 16, 2016-Horizon Pharma expects US patent for RAVICTI (glycerol phenylbutyrate) Oral Liquid for UCDs
M2 PHARMA-March 16, 2016-Horizon Pharma expects US patent for RAVICTI (glycerol phenylbutyrate) Oral Liquid for UCDs
M2 EQUITYBITES-June 24, 2015-Horizon Pharma anticipates additionsl US patent covering RAVICTI (Glycerol Phenylbutyrate) Oral Liquid for use as nitrogen-binding agent
M2 PHARMA-June 24, 2015-Horizon Pharma anticipates additionsl US patent covering RAVICTI (Glycerol Phenylbutyrate) Oral Liquid for use as nitrogen-binding agent
Biopharmaceutical company Hyperion Therapeutics (NasdaqGS:HPTX) said on Wednesday that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorisation Application (MAA) for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs).
Hyperion Therapeutics (NASDAQ: HPTX), a biopharmaceutical company, has received acceptance from Health Canada for its new drug submission and priority review for Ravicti (glycerol phenylbutyrate) Oral Liquid, indicated to treat urea cycle disorders, it was reported yesterday.
Biopharmaceutical company Hyperion Therapeutics (NasdaqGS:HPTX) disclosed on Tuesday the receipt of Health Canada's priority review for its New Drug Submission (NDS) for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs) .